Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a report released on Thursday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Price Performance

Shares of Galmed Pharmaceuticals stock opened at $2.26 on Thursday. Galmed Pharmaceuticals has a fifty-two week low of $1.67 and a fifty-two week high of $23.80. The firm has a market capitalization of $1.46 million, a P/E ratio of -0.14 and a beta of 0.72. The company’s 50 day moving average price is $2.48 and its two-hundred day moving average price is $3.41.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is owned by hedge funds and other institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.